IDE Human

Insulin-Degrading Enzyme Human Recombinant
Shipped with Ice Packs
In Stock

Description

Substrate Specificity and Catalytic Mechanism

Key Substrates:

SubstrateBiological RoleCleavage Pattern
InsulinGlucose homeostasisProcessive degradation of A/B chains
Amyloid-β (Aβ)Alzheimer’s disease pathologyNon-processive cleavage
GlucagonCounter-regulatory hormoneSingle-site hydrolysis
AmylinSatiety regulationβ-sheet stabilization

Mechanistic Features:

  • Size/charge selectivity: The catalytic chamber selectively traps substrates via complementary electrostatic surfaces .

  • Processivity: Insulin is degraded without disrupting disulfide bonds, facilitated by IDE’s ability to stabilize substrate β-sheets while repositioning cleavage sites .

  • Conformational regulation: Mutations favoring the "open" conformation increase catalytic activity 40-fold .

Therapeutic Implications

IDE Modulation Strategies:

Compound/ApproachEffect on IDEClinical Relevance
D3, D4, D6, D10Enhance Aβ/insulin degradationAlzheimer’s/diabetes therapy
BDM44768, Ii1Pan-substrate inhibitionHyperinsulinemia control
6bKAβ-selective inhibitionNeuroprotection
Gene overexpressionReduces cerebral Aβ levelsAlzheimer’s intervention

Structural studies reveal that IDE activators (e.g., D10) stabilize substrate interactions at exosites, while inhibitors (e.g., BDM44768) block catalytic zinc coordination . Cryo-EM analyses demonstrate that IDE’s dynamic conformational changes enable substrate-assisted catalysis, particularly for amyloidogenic peptides .

Disease Associations

  • Diabetes: IDE knockout mice exhibit glucose intolerance and insulin resistance .

  • Alzheimer’s disease: IDE deficiency correlates with Aβ accumulation, while its upregulation reduces amyloid plaques .

  • Cancer: Overexpression in neuroblastoma promotes proliferation, making IDE a potential oncology target .

Research Advances

  • Cryo-EM insights: IDE’s "tethered release" mechanism explains selective degradation of amyloidogenic peptides .

  • Substrate-assisted catalysis: Aβ stabilizes IDE’s disordered catalytic cleft, enhancing its own degradation .

  • Isoform-specific roles: The truncated isoform 2 may regulate full-length IDE activity, though its exact function remains unclear .

Product Specs

Introduction

Insulin-Degrading Enzyme (IDE) is a zinc metallopeptidase responsible for degrading intracellular insulin, thereby ending its activity. It also contributes to intercellular peptide signaling by breaking down various peptides such as amylin, bradykinin, and kallidin. IDE's strong affinity for insulin leads to insulin-mediated inhibition of the degradation of other peptides like beta-amyloid. Impaired IDE function is associated with Alzheimer's disease and type 2 diabetes mellitus, although mutations in the IDE gene haven't been proven as a direct cause of these diseases. IDE is primarily found in the cytoplasm, but in certain cell types, it can also be located in the extracellular space, cell membrane, peroxisome, and mitochondrion. Moreover, IDE degrades amyloid generated by APP and IAPP and participates in the degradation and clearance of naturally secreted amyloid beta-protein by neurons and microglia.

Description
Recombinant human IDE, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 1026 amino acids. This includes the 1019 amino acids of IDE (Met1-Leu1019) and a 7 amino acid His tag located at the C-terminus. The calculated molecular mass of the protein is 119kDa.
Physical Appearance
A clear, colorless solution that has been filtered.
Formulation

IDE, filtered through a 0.4µm filter, is supplied in a solution of 20mM Tris buffer, 50mM NaCl, at pH 8.0, with 10% (w/v) glycerol.

Stability
For short-term storage (2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is advisable for long-term storage. Repeated freezing and thawing of the product should be avoided.
Purity
The purity of IDE is determined to be greater than 95% using SDS-PAGE analysis.
Synonyms
Insulin-Degrading Enzyme, Abeta-Degrading Protease, Insulin Protease, EC 3.4.24.56, Insulinase, INSULYSIN, Insulysin, EC 3.4.24, IDE.
Source
Escherichia Coli.
Amino Acid Sequence
MRYRLAWLLH PALPSTFRSV LGARLPPPER LCGFQKKTYS KMNNPAIKRI GNHITKSPED KREYRGLELA NGIKVLLISD PTTDKSSAAL DVHIGSLSDP PNIAGLSHFC EHMLFLGTKK YPKENEYSQF LSEHAGSSNA FTSGEHTNYY FDVSHEHLEG ALDRFAQFFL CPLFDESCKD REVNAVDSEH EKNVMNDAWR LFQLEKATGN PKHPFSKFGT GNKYTLETRP NQEGIDVRQE LLKFHSAYYS SNLMAVCVLG RESLDDLTNL VVKLFSEVEN KNVPLPEFPE HPFQEEHLKQ LYKIVPIKDI RNLYVTFPIP DLQKYYKSNP GHYLGHLIGH EGPGSLLSEL KSKGWVNTLV GGQKEGARGF MFFIINVDLT EEGLLHVEDI ILHMFQYIQK LRAEGPQEWV FQECKDLNAV AFRFKDKERP RGYTSKIAGI LHYYPLEEVL TAEYLLEEFR PDLIEMVLDK LRPENVRVAI VSKSFEGKTD RTEEWYGTQY KQEAIPDEVI KKWQNADLNG KFKLPTKNEF IPTNFEILPL EKEATPYPAL IKDTAMSKLW FKQDDKFFLP KACLNFEFFS PFAYVDPLHC NMAYLYLELL KDSLNEYAYA AELAGLSYDL QNTIYGMYLS VKGYNDKQPI LLKKIIEKMA TFEIDEKRFE IIKEAYMRSL NNFRAEQPHQ HAMYYLRLLM TEVAWTKDEL KEALDDVTLP RLKAFIPQLL SRLHIEALLH GNITKQAALG IMQMVEDTLI EHAHTKPLLP SQLVRYREVQ LPDRGWFVYQ QRNEVHNNCG IEIYYQTDMQ STSENMFLEL FCQIISEPCF NTLRTKEQLG YIVFSGPRRA NGIQGLRFII QSEKPPHYLE SRVEAFLITM EKSIEDMTEE AFQKHIQALA IRRLDKPKKL SAECAKYWGE IISQQYNFDR DNTEVAYLKT LTKEDIIKFY KEMLAVDAPR RHKVSVHVLA REMDSCPVVG EFPCQNDINL SQAPALPQPE VIQNMTEFKR GLPLFPLVKP HINFMAAKL E HHHHHH.

Q&A

What is IDE in the context of human research?

IDE has two primary meanings in research contexts: Insulin-Degrading Enzyme, a metalloprotease involved in the clearance of insulin and amyloid-β peptides, and Industrial Design Engineering, a discipline focused on human-centered design research. Insulin-Degrading Enzyme plays a critical role in degrading various peptide hormones and has implications for conditions like Alzheimer's disease and diabetes. Industrial Design Engineering research at institutions like TU Delft focuses on themes of Health, Mobility, and Sustainability with perspectives on People, Technology, and Organisation .

How does human IDE structure relate to its function?

Human Insulin-Degrading Enzyme consists of amino- and carboxy-terminal domains (IDE-N and IDE-C) that form an enclosed cage just large enough to encapsulate insulin and other peptide substrates. This unique structural arrangement creates a degradation chamber that remains inaccessible to substrates until the IDE domains reposition. The size and charge distribution of the substrate-binding cavity enable IDE to selectively entrap structurally diverse polypeptides. This explains IDE's remarkable capacity to cleave certain hormones selectively without degrading related family members .

What are the primary research themes in IDE human studies?

For Insulin-Degrading Enzyme research, primary themes include investigating its role in:

  • Insulin clearance and glucose homeostasis

  • Amyloid-β degradation and Alzheimer's disease pathology

  • Processing of other bioactive peptides (amylin, glucagon)

  • Structural biology of substrate recognition and enzymatic action

For Industrial Design Engineering human research, key themes include:

  • Health: Human-centered design for healthcare solutions

  • Mobility: Design for sustainable transportation and movement

  • Sustainability: Environmentally conscious design approaches

  • Designing Design: Meta-research on design methodologies

How should researchers address selective reporting in IDE-related experiments?

  • Define inclusion and exclusion criteria for experiments before seeing the results

  • Preregister hypotheses and methods when conducting confirmatory research

  • Report all conducted experiments, even those with negative or inconclusive results

  • Clearly mark and disclose any post-hoc decisions for considering experiments as unreliable

  • Never use agreement with predictions or previous findings as criteria for including an experiment

This approach helps prevent the "file drawer effect" where inconvenient results remain unpublished and helps mitigate HARKing (Hypothesizing After Results are Known) .

What experimental validation approaches are recommended for IDE structural studies?

When conducting structural studies of human IDE complexed with substrates, researchers should:

  • Implement predefined validation criteria for experimental outcomes

  • Establish clear parameters for what constitutes a successful experiment versus a methodological failure

  • Document all experimental attempts with both successful and unsuccessful outcomes

  • Validate findings across multiple substrates (e.g., insulin B chain, amyloid-β peptide, amylin, glucagon)

  • Correlate structural findings with functional assays to confirm biological relevance

These approaches ensure reproducibility and prevent bias in structural biology research on complex enzymes like IDE .

How can researchers effectively map interconnections within IDE research communities?

Based on successful approaches at TU Delft's Faculty of Industrial Design, researchers can map interconnections through:

  • Creating comprehensive surveys asking researchers to:

    • List expertise using specific keywords

    • Associate their research with fundamental platforms identified in the field

    • Identify collaborative networks

  • Developing visualizations of research interconnectedness showing:

    • Overlapping research interests

    • Cross-disciplinary collaborations

    • Thematic clusters within the broader research community

This mapping approach has proven valuable for both organizing research content and identifying collaborative opportunities within IDE research communities .

What IRB considerations apply to human research involving IDE?

Human research involving IDE (either enzyme studies or industrial design engineering) requires careful consideration of:

  • Determination of whether the research requires IRB review (not all IDE research needs IRB approval)

  • Proper submission procedures through institutional HRPP (Human Research Protection Program)

  • Addressing data security and confidentiality concerns, particularly with sensitive biological samples or personal design research data

  • Understanding the distinctions between quality improvement activities and formal research

  • Ensuring appropriate consent processes when human participants are involved

Researchers should consult their institution's Investigator Manual or equivalent resource for specific guidance on navigating IRB requirements .

How should researchers approach data and specimen activities in IDE human research?

When working with human data or specimens in IDE research:

  • Determine whether secondary use research requires consent:

    • Consider the identifiability of samples/data

    • Assess the original consent parameters

    • Evaluate regulatory requirements for different specimen types

  • Establish protocols for sharing identifiable data or specimens with collaborators:

    • Material Transfer Agreements (MTAs) may be required

    • Data sharing agreements should address confidentiality

  • For biospecimens sent outside the institution:

    • Follow institutional policies for transfer

    • Ensure proper documentation and tracking

    • Address any intellectual property considerations

These considerations apply to both biological samples containing Insulin-Degrading Enzyme and human data collected during Industrial Design Engineering research .

How can researchers develop robust data and safety monitoring plans for IDE studies?

Effective data and safety monitoring plans for IDE research should:

  • Establish clear validation criteria before experiments begin

  • Document all experimental attempts, even unsuccessful ones

  • Implement consistent data preprocessing pipelines, particularly for high-throughput studies

  • Set objective criteria for defining outliers or problematic data points

  • Create independent monitoring mechanisms when appropriate

These measures help prevent post-hoc rationalization of experimental failures and reduce researcher bias in data interpretation and reporting .

What approaches are recommended for integrating artificial intelligence tools in IDE human research?

When incorporating AI tools in IDE human research, researchers should consider:

  • Potential issues during submission:

    • Data security concerns

    • Limitations of AI data entry

    • Copyright considerations

  • For intervention-based research with AI tools:

    • Provide detailed information about AI mechanisms

    • Address potential biases in AI algorithms

    • Document validation procedures for AI outputs

  • Participant information requirements:

    • Clear disclosure about AI involvement

    • Explanation of data usage and privacy safeguards

    • Description of limitations in AI-based interventions

These considerations ensure ethical integration of AI tools while maintaining scientific rigor in IDE research .

How does the structure of human IDE contribute to its substrate selectivity?

Human IDE's unique structural features contribute to its remarkable substrate selectivity through:

  • Formation of an enclosed catalytic chamber:

    • IDE-N and IDE-C domains create a cage-like structure

    • The chamber size is precisely calibrated to fit insulin and similar-sized peptides

  • Substrate access mechanism:

    • Repositioning of IDE domains controls substrate entry

    • Extensive contacts between domains regulate access to the degradation chamber

  • Selective substrate entrapment:

    • Size and charge distribution within the binding cavity enable recognition of diverse polypeptides

    • This explains IDE's ability to selectively cleave certain hormones while sparing related family members

This structural arrangement allows IDE to perform its biological functions with specificity despite the diversity of its substrates .

What methodological approaches are recommended for studying IDE-substrate interactions?

To effectively study IDE-substrate interactions, researchers should:

  • Employ multiple complementary techniques:

    • X-ray crystallography for static structural analysis

    • Molecular dynamics simulations for understanding conformational changes

    • Biochemical assays for enzyme kinetics and substrate preference

  • Analyze multiple substrate types:

    • Include diverse peptides (insulin B chain, amyloid-β, amylin, glucagon)

    • Compare binding and cleavage patterns across substrate families

  • Investigate both binding and catalytic events:

    • Study initial substrate recognition

    • Analyze intermediate steps in the degradation process

    • Examine product release mechanisms

This comprehensive approach provides deeper insights into IDE's selective yet broad substrate recognition capacity .

Product Science Overview

Historical Context

IDE was first identified over sixty years ago due to its ability to degrade the B chain of insulin . The enzyme responsible for this activity was later identified and characterized. The discovery of IDE’s role in insulin degradation has significant implications for understanding insulin regulation and its termination of activity in insulin-responsive tissues .

Structural and Functional Insights

IDE is composed of two homologous ~55 kDa N- and C-terminal halves, which form a large opening that allows selective substrate capture based on size and charge complementarity . This structural feature is crucial for IDE’s ability to degrade amyloidogenic peptides, including insulin and amyloid β-protein (Aβ), which are associated with type 2 diabetes mellitus and Alzheimer’s disease .

Mechanism of Action

IDE degrades insulin by stochastically cutting either chain without breaking disulfide bonds . This processive degradation is facilitated by the enzyme’s catalytic cleft, which is stabilized by amyloidogenic peptides through substrate-assisted catalysis . The enzyme’s ability to degrade various peptides, such as amylin, bradykinin, and kallidin, highlights its role in intercellular peptide signaling .

Recombinant Expression

The human recombinant form of IDE has been successfully expressed in Chinese hamster ovary cells using a plasmid containing the IDE cDNA under the transcriptional control of the SRα promoter . The recombinant protein synthesized by these cells is indistinguishable from the isolated human enzyme in both size and immunoreactivity, and it degrades insulin with a specific activity similar to that of the purified proteinase .

Clinical Implications

IDE’s role in degrading insulin and amyloidogenic peptides makes it a potential therapeutic target for diseases such as type 2 diabetes and Alzheimer’s disease . Understanding the molecular basis of IDE’s function and its interaction with substrates can aid in the development of IDE-based therapies .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.